Drug combo in AML: how antifungal affects cancer treatment levels

NCT ID NCT07254611

Completed Knowledge-focused Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how the antifungal drug posaconazole affects blood levels of the cancer drug venetoclax in 15 adults with acute myeloid leukemia (AML) who were also receiving a hypomethylating agent (azacitidine or decitabine). The goal was to see how many patients reached stable venetoclax levels by day 12 of treatment. The findings could help doctors adjust venetoclax doses to avoid toxicity while preserving its anti-leukemia effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax and posaconazole
What this could lead to: If successful, this could help doctors safely adjust venetoclax doses when giving posaconazole, reducing toxicity while maintaining treatment effectiveness.
What could go wrong: This is a small, completed pharmacokinetic study (15 participants) that only measured drug levels, not treatment outcomes. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOGENOUS LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML (ACUTE MYELOGENOUS LEUKEMIA)

Contacts and locations

Locations

Fondazione IRCCS Policlinico San Matteo

Pavia, Lombardy, 27100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.